Otsuka Pharmaceutical Co Ltd v. Sandoz Inc

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Otsuka Pharmaceutical Co., Ltd. (Japan)
  • Defendant: Sandoz Inc. (Delaware)
  • Plaintiff's Counsel: Morris, Nichols, Arsht & Tunnell LLP (Lead Counsel); Venable LLP (Of Counsel)
• Case Identification: 1:26-cv-00232, D. Del., 03/05/2026
• Venue Allegations: Venue is asserted in the District of Delaware based on Defendant Sandoz Inc.'s incorporation in the state of Delaware.
• Core Dispute: Plaintiff alleges that Defendant's filing of an Abbreviated New Drug Application (ANDA) to market generic tolvaptan tablets constitutes an act of patent infringement under the Hatch-Waxman Act, infringing patents related to the drug's formulation and its manufacturing process.
• Technical Context: The technology concerns pharmaceutical formulations designed to improve the solubility and bioavailability of tolvaptan, an active ingredient used to treat autosomal dominant polycystic kidney disease (ADPKD).
• Key Procedural History: The litigation was triggered by a "Notice of Paragraph IV Certification" letter sent by Sandoz to Otsuka on January 21, 2026. This letter notified Otsuka of Sandoz's ANDA filing (No. 220654) and asserted that the patents-in-suit are invalid, unenforceable, and/or would not be infringed by Sandoz's proposed generic product. Otsuka filed this complaint within the 45-day statutory window, which triggers an automatic 30-month stay of FDA approval for Sandoz's ANDA.

Case Timeline

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 10,905,694 - "Pharmaceutical Solid Preparation Comprising Benzazepines and Production Method Thereof" (Issued Feb. 2, 2021)

The Invention Explained

• Problem Addressed: The patent's background section identifies a key challenge with the active pharmaceutical ingredient (API), a benzoazepine compound known as tolvaptan: its poor solubility results in low and inconsistent absorption by the body from the gastrointestinal tract Compl. ¶16 '694 Patent, col. 1:31-34 Furthermore, simply compressing an amorphous, more soluble form of the drug into a tablet fails because the resulting tablet does not properly disintegrate, rendering the drug ineffective '694 Patent, col. 1:40-44
• The Patented Solution: The invention is a specific pharmaceutical formulation and production method that overcomes these issues. It involves creating an amorphous composite of the tolvaptan API and hydroxypropylcellulose, granulating this composite with other excipients like cellulose and corn starch, and then mixing these granules with a specific type of disintegrant-"low substituted hydroxypropylcellulose" having a defined particle size distribution-before final processing into a solid tablet '694 Patent, abstract '694 Patent, col. 2:10-24 This multi-step process and specific combination of ingredients are claimed to yield a tablet that both disintegrates rapidly and provides for effective absorption of the poorly soluble drug.
• Technical Importance: The claimed formulation provides a technical solution for delivering a therapeutically important but poorly soluble drug in a reliable solid oral dosage form, which is critical for consistent patient dosing and clinical efficacy.

Key Claims at a Glance

• The complaint asserts infringement of at least independent claim 1 Compl. ¶32
• Claim 1 is a method claim for producing a pharmaceutical solid preparation, comprising the essential elements of:
  • Step 1: Producing "amorphous composites" consisting of the tolvaptan API and a specific hydroxypropylcellulose.
  • Step A: Processing a mixture of the amorphous composites, crystalline cellulose, and corn starch and/or lactose into "granules" via a granulation method.
  • Step 2: Mixing the granules with a "low substituted hydroxypropylcellulose" that possesses specific, claimed properties (cellulose containing a hydroxy propoxyl group of about 10-13%, an average particle diameter of 45-65 µm, and a 90% cumulative particle diameter of 150-200 µm).
  • Step 3: Processing the resulting mixture into a solid preparation.
• The complaint broadly alleges infringement of "one or more claims" of the '694 Patent, which may encompass dependent claims not explicitly identified Compl. ¶32

U.S. Patent No. 8,273,735 - "Process for Preparing Benzazepine Compounds or Salts Thereof" (Issued Sep. 25, 2012)

The Invention Explained

• Problem Addressed: The patent describes prior art methods for synthesizing benzazepine compounds (like tolvaptan) as unsuitable for industrial-scale production due to issues with yield and purity '735 Patent, col. 2:49-57
• The Patented Solution: The invention provides an improved, industrially scalable chemical process for manufacturing the target compounds. The core of the claimed process involves reacting a specific benzazepine-ring-containing intermediate with a separate amide compound in the presence of a "carbonylating agent" (e.g., carbon monoxide with a catalyst) to form the final tolvaptan molecule '735 Patent, abstract '735 Patent, col. 3:50-col. 4:2 This process is asserted to produce the desired compound in high yield and high purity.
• Technical Importance: The invention provides an efficient and scalable synthesis route for a key pharmaceutical compound, a critical requirement for viable commercial manufacturing of a drug.

Key Claims at a Glance

• The complaint asserts infringement of at least claims 6-8 and 10 Compl. ¶41
• Independent claim 1, on which the asserted claims depend, recites a process for producing a class of benzazepine compounds. Its essential elements are:
  • Reacting a benzazepine compound of formula (2).
  • With an amide compound of formula (3).
  • In the presence of a "carbonylating agent."
• Asserted claim 6 narrows this process to the production of the specific compound tolvaptan (or its 5-one precursor).

III. The Accused Instrumentality

• Product Identification: Sandoz's ANDA Products, which are tolvaptan tablets proposed in 15, 30, 45, 60, and 90 mg dosage strengths Compl. ¶2
• Functionality and Market Context: The accused products are generic versions of Otsuka's JYNARQUE® brand tolvaptan tablets Compl. ¶23 JYNARQUE® is a prescription drug approved to slow the decline of kidney function in adults with rapidly progressing autosomal dominant polycystic kidney disease (ADPKD) Compl. ¶14 The complaint alleges that Sandoz's ANDA represents to the FDA that its products are "pharmaceutically and therapeutically equivalent" to JYNARQUE® Compl. ¶30 The act of infringement alleged under 35 U.S.C. § 271(e)(2) is the submission of the ANDA itself, which seeks FDA approval to market these generic versions before the expiration of Otsuka's patents Compl. ¶32

IV. Analysis of Infringement Allegations

The complaint, characteristic of initial pleadings in ANDA litigation, does not provide a detailed claim chart or specific factual allegations mapping claim elements to the accused product's formulation or manufacturing process. The infringement allegations are based on the statutory act of Sandoz's ANDA submission.

No probative visual evidence provided in complaint.

'694 Patent Infringement Allegations

The core theory of infringement is that by filing an ANDA for a product represented as pharmaceutically equivalent to JYNARQUE®, Sandoz necessarily seeks approval for a product that embodies the formulation claimed in the '694 Patent Compl. ¶30 Compl. ¶32 The complaint alleges that if Sandoz's ANDA is approved, its commercial manufacture, use, or sale of the tolvaptan tablets will directly infringe one or more claims Compl. ¶34

'735 Patent Infringement Allegations

The complaint asserts a declaratory judgment of infringement, alleging that Sandoz has made "substantial and meaningful preparations" to import, use, or sell a product (its tolvaptan tablets) that is "made by a process patented by the '735 Patent" Compl. ¶39 This allegation of infringement under 35 U.S.C. § 271(g) rests on the premise that the API in Sandoz's ANDA Products will be manufactured using the patented chemical synthesis process Compl. ¶41

• Identified Points of Contention:
  • Technical Questions (Composition): A primary issue for the '694 Patent will be whether Sandoz's proposed generic formulation, as described in its confidential ANDA, contains every element of the asserted claims. Discovery will focus on whether Sandoz uses a "low substituted hydroxypropylcellulose" and whether that excipient meets the specific particle diameter and cumulative particle diameter limitations recited in claim 1.
  • Technical Questions (Process): For the '735 Patent, the central dispute will be factual: what chemical process does Sandoz or its API supplier use to synthesize tolvaptan? The analysis will turn on whether that process involves the claimed reaction of specific intermediates in the presence of a "carbonylating agent."

V. Key Claim Terms for Construction

• The Term: "low substituted hydroxypropylcellulose...has an average particle diameter of 45 to 65 µm, and has a 90% cumulative particle diameter of 150 to 200 µm" ('694 Patent, claim 1, incorporating limitations from the specification).
• Context and Importance: This term defines a critical excipient with precise physical characteristics. Sandoz's non-infringement defense for the '694 Patent may depend on demonstrating that its chosen disintegrant falls outside these specific numerical ranges or is a different material altogether.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The specification introduces a broader group of potential disintegrants in "Item 1," including carmellose and crospovidone, before focusing on the specific low substituted hydroxypropylcellulose '694 Patent, col. 2:17-24 While this may not broaden the term in the specific asserted claim, it provides context about the function of the claimed element.
  • Evidence for a Narrower Interpretation: The patent repeatedly emphasizes the importance of these specific particle sizes for achieving the invention's superior disintegration properties, distinguishing it from other types of hydroxypropylcellulose that failed to work '694 Patent, col. 19:35-41 '694 Patent, Table 1 The prosecution history may also contain statements distinguishing the invention from prior art based on these precise parameters, which could be used to argue for a narrow construction.

VI. Other Allegations

• Indirect Infringement: The complaint includes forward-looking allegations that, upon FDA approval, Sandoz will actively induce and contribute to infringement of the '694 Patent by marketing its generic product Compl. ¶34
• Willful Infringement: The complaint does not use the term "willful." However, it lays a foundation for a potential future claim by alleging Sandoz has "actual knowledge" of the '694 Patent and had "actual and constructive notice" of the '735 Patent prior to filing its ANDA Compl. ¶31 Compl. ¶42

VII. Analyst's Conclusion: Key Questions for the Case

This litigation presents a classic Hatch-Waxman dispute centered on both the final drug product formulation and the underlying API manufacturing process. The case will likely turn on the following key questions:

• A question of compositional identity: Does the confidential formulation in Sandoz's ANDA replicate the specific recipe of the '694 Patent, particularly the use of a "low substituted hydroxypropylcellulose" meeting the patent's precise particle size limitations, or has Sandoz successfully designed around this claimed feature?
• A question of process tracing: Will discovery reveal that the synthesis route for Sandoz's tolvaptan API employs the chemical reaction defined in the '735 Patent-specifically the use of a "carbonylating agent" to join two key intermediates-or does it utilize a distinct, non-infringing manufacturing process?
• A question of validity: As raised in Sandoz's Paragraph IV certification, will the court find the claimed formulation in the '694 Patent to be an unobvious invention, or will it be deemed an obvious combination of known pharmaceutical excipients that a skilled formulator would have been motivated to try to solve tolvaptan's known solubility problems?